Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

Allan Lipton, Harold A. Harvey, Bellarmine Lawrence, Robert Gottlieb, Miodrag Kukrika, Richard Dixon, William Graham, Stephen Miller, Robert Heckard, Dale Schelzel, Deborah S. White

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


One‐hundred and sixteen patients with Stage I and Stage II malignant melanoma were randomized to treatment with either Bacillus Calmette‐Guerin (BCG) (Tice) or subcutaneous Corynebacterium parvum (Burroughs‐Wellcome). Life table analysis failed to reveal a difference between these two forms of treatment in 68 Stage I patients. The relapse rate was significantly reduced in Stage II patients trated with C. parvum.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
Issue number1
StatePublished - Jan 1 1983

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma'. Together they form a unique fingerprint.

Cite this